Home › Premarket Biotech Digest: Gilead's Upcoming Earnings, Setback For AstraZeneca, Zafgen Tumbles 50%
 

Keywords :   


Premarket Biotech Digest: Gilead's Upcoming Earnings, Setback For AstraZeneca, Zafgen Tumbles 50%

2015-10-19 16:04:07| Biotech - Topix.net

The consensus forecast for Q3 revenue is at $7.81 billion, which is below the $8.24 billion reported in the previous quarter. The slight decline in revenue is due to a slowdown in the U.S. Hep C sales.

Tags: upcoming earnings digest biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.05Is Zimbabwe zigzagging into further currency chaos?
05.05Why mortgage rates are going up, not down
04.05This Week in Agribusiness, May 4, 2024
04.05Weekly Recap: Sherwin-Williams, BASF, Abrafati Top This Weeks Stories
03.05'Garden floods show need to work with nature'
03.05Worst-ever job interviews: 'We had to crawl and moo'
03.05Have the wheels come off for Tesla?
03.05BW Converting focuses on time, energy and cost savings at INFOFLEX
More »